BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 38231344)

  • 21. Redirecting Specificity of T cells Using the Sleeping Beauty System to Express Chimeric Antigen Receptors by Mix-and-Matching of VL and VH Domains Targeting CD123+ Tumors.
    Thokala R; Olivares S; Mi T; Maiti S; Deniger D; Huls H; Torikai H; Singh H; Champlin RE; Laskowski T; McNamara G; Cooper LJ
    PLoS One; 2016; 11(8):e0159477. PubMed ID: 27548616
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lactate dehydrogenase-release assay: a reliable, nonradioactive technique for analysis of cytotoxic lymphocyte-mediated lytic activity against blasts from acute myelocytic leukemia.
    Weidmann E; Brieger J; Jahn B; Hoelzer D; Bergmann L; Mitrou PS
    Ann Hematol; 1995 Mar; 70(3):153-8. PubMed ID: 7718644
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Immunotherapy for leukemia cells by using cytotoxic T lymphocyte specifically against WT1-derived peptide: an experimental study in vitro].
    Gu WY; Cao XS; Qiu GQ; Chen ZX; Sheng LX; Xie XB; He J; Cen JN; Shen HL
    Zhonghua Yi Xue Za Zhi; 2005 Dec; 85(49):3475-80. PubMed ID: 16686063
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CD4
    Perugino CA; Kaneko N; Maehara T; Mattoo H; Kers J; Allard-Chamard H; Mahajan VS; Liu H; Della-Torre E; Murphy SJH; Ghebremichael M; Wallace ZS; Bolster MB; Harvey LM; Mylvaganam G; Tuncay Y; Liang L; Montesi SB; Zhang X; Tinju A; Mochizuki K; Munemura R; Sakamoto M; Moriyama M; Nakamura S; Yosef N; Stone JH; Pillai S
    J Allergy Clin Immunol; 2021 Jan; 147(1):368-382. PubMed ID: 32485263
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Optimization of Human NK Cell Manufacturing: Fully Automated Separation, Improved Ex Vivo Expansion Using IL-21 with Autologous Feeder Cells, and Generation of Anti-CD123-CAR-Expressing Effector Cells.
    Klöß S; Oberschmidt O; Morgan M; Dahlke J; Arseniev L; Huppert V; Granzin M; Gardlowski T; Matthies N; Soltenborn S; Schambach A; Koehl U
    Hum Gene Ther; 2017 Oct; 28(10):897-913. PubMed ID: 28810809
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bone marrow-derived T-cell clones obtained from untreated acute myelocytic leukemia exhibit blast directed autologous cytotoxicity.
    Jahn B; Bergmann L; Weidmann E; Brieger J; Fenchel K; Schwulera U; Hoelzer D; Mitrou PS
    Leuk Res; 1995 Feb; 19(2):73-82. PubMed ID: 7869744
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CD80-Transfected acute myeloid leukemia cells induce primary allogeneic T-cell responses directed at patient specific minor histocompatibility antigens and leukemia-associated antigens.
    Mutis T; Schrama E; Melief CJ; Goulmy E
    Blood; 1998 Sep; 92(5):1677-84. PubMed ID: 9716596
    [TBL] [Abstract][Full Text] [Related]  

  • 28. IDO-independent suppression of T cell effector function by IFN-γ-licensed human mesenchymal stromal cells.
    Chinnadurai R; Copland IB; Patel SR; Galipeau J
    J Immunol; 2014 Feb; 192(4):1491-501. PubMed ID: 24403533
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Systematic preclinical evaluation of CD33-directed chimeric antigen receptor T cell immunotherapy for acute myeloid leukemia defines optimized construct design.
    Qin H; Yang L; Chukinas JA; Shah N; Tarun S; Pouzolles M; Chien CD; Niswander LM; Welch AR; Taylor N; Tasian SK; Fry TJ
    J Immunother Cancer; 2021 Sep; 9(9):. PubMed ID: 34531250
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CAR-T cells targeting CLL-1 as an approach to treat acute myeloid leukemia.
    Wang J; Chen S; Xiao W; Li W; Wang L; Yang S; Wang W; Xu L; Liao S; Liu W; Wang Y; Liu N; Zhang J; Xia X; Kang T; Chen G; Cai X; Yang H; Zhang X; Lu Y; Zhou P
    J Hematol Oncol; 2018 Jan; 11(1):7. PubMed ID: 29316944
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tandem bispecific CD123/CLL-1 CAR-T cells exhibit specific cytolytic effector functions against human acute myeloid leukaemia.
    Wang XY; Bian MR; Lin GQ; Yu L; Zhang YM; Wu DP
    Eur J Haematol; 2024 Jan; 112(1):83-93. PubMed ID: 37712633
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Acute myeloid leukemia induces protumoral p16INK4a-driven senescence in the bone marrow microenvironment.
    Abdul-Aziz AM; Sun Y; Hellmich C; Marlein CR; Mistry J; Forde E; Piddock RE; Shafat MS; Morfakis A; Mehta T; Di Palma F; Macaulay I; Ingham CJ; Haestier A; Collins A; Campisi J; Bowles KM; Rushworth SA
    Blood; 2019 Jan; 133(5):446-456. PubMed ID: 30401703
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Indoleamine 2,3-dioxygenase and regulatory T cells in acute myeloid leukemia.
    Mansour I; Zayed RA; Said F; Latif LA
    Hematology; 2016 Sep; 21(8):447-53. PubMed ID: 27077762
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical grade expansion of CD45RA, CD45RO, and CD62L-positive T-cell lines from HLA-compatible donors: high cytotoxic potential against AML and ALL cells.
    Barbui AM; Borleri G; Conti E; Ciocca A; Salvi A; Micò C; Introna M; Rambaldi A
    Exp Hematol; 2006 Apr; 34(4):475-85. PubMed ID: 16569594
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunoregulatory effects on T lymphocytes by human mesenchymal stromal cells isolated from bone marrow, amniotic fluid, and placenta.
    Mareschi K; Castiglia S; Sanavio F; Rustichelli D; Muraro M; Defedele D; Bergallo M; Fagioli F
    Exp Hematol; 2016 Feb; 44(2):138-150.e1. PubMed ID: 26577566
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Allogeneic FLT3 CAR T Cells with an Off-Switch Exhibit Potent Activity against AML and Can Be Depleted to Expedite Bone Marrow Recovery.
    Sommer C; Cheng HY; Nguyen D; Dettling D; Yeung YA; Sutton J; Hamze M; Valton J; Smith J; Djuretic I; Chaparro-Riggers J; Sasu BJ
    Mol Ther; 2020 Oct; 28(10):2237-2251. PubMed ID: 32592688
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mesenchymal stromal cells from myelodysplastic and acute myeloid leukemia patients display in vitro reduced proliferative potential and similar capacity to support leukemia cell survival.
    Corradi G; Baldazzi C; Očadlíková D; Marconi G; Parisi S; Testoni N; Finelli C; Cavo M; Curti A; Ciciarello M
    Stem Cell Res Ther; 2018 Oct; 9(1):271. PubMed ID: 30359303
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Alteration Analysis of Bone Marrow Mesenchymal Stromal Cells from De Novo Acute Myeloid Leukemia Patients at Diagnosis.
    Desbourdes L; Javary J; Charbonnier T; Ishac N; Bourgeais J; Iltis A; Chomel JC; Turhan A; Guilloton F; Tarte K; Demattei MV; Ducrocq E; Rouleux-Bonnin F; Gyan E; Hérault O; Domenech J
    Stem Cells Dev; 2017 May; 26(10):709-722. PubMed ID: 28394200
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mesenchymal stem cell suppresses the efficacy of CAR-T toward killing lymphoma cells by modulating the microenvironment through stanniocalcin-1.
    Zhang R; Liu Q; Zhou S; He H; Zhao M; Ma W
    Elife; 2023 Feb; 12():. PubMed ID: 36779699
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Optimized depletion of chimeric antigen receptor T cells in murine xenograft models of human acute myeloid leukemia.
    Tasian SK; Kenderian SS; Shen F; Ruella M; Shestova O; Kozlowski M; Li Y; Schrank-Hacker A; Morrissette JJD; Carroll M; June CH; Grupp SA; Gill S
    Blood; 2017 Apr; 129(17):2395-2407. PubMed ID: 28246194
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.